Table 1.
Clinical Indications for direct oral factor X inhibitors
| Drug | Initial FDA approval | Approved clinical indications |
|---|---|---|
| Rivaroxaban | November 4, 2011 | AF |
| VTE prevention+ ,# | ||
| VTE Treatment ** | ||
| VTE Treatment-extendedO | ||
| CCAD | ||
| PAD | ||
| Apixaban | December 28, 2012 | AF |
| VTE Prevention+ | ||
| VTE treatment** | ||
| Endoxaban | June 23, 2017 | AF |
| VTE Treatment+ + | ||
| Betrixaban | January 8, 2015 | VTE Prevention# |
AF atrial fibrillation, VTE venous thromboembolism, CCAD chronic coronary artery disease, PAD peripheral arterial disease
*As of December 1, 2010
+Following hip or knee replacement surgery
**Deep vein thrombosis and pulmonary embolism
++In patients already treated with parenteral anticoagulants for 5–10 days
#In adult patients hospitalized for an acute medical illness at risk for thromboembolic events
OFor patients at risk for recurrent VTE after completing 6 months of treatment